- Home
- CYBR vs PCVX Comparison
CYBR vs PCVX Comparison
Compare CYBR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBR
- PCVX
- Stock Information
- Founded
- CYBR 1999
- PCVX 2013
- Country
- CYBR Israel
- PCVX United States
- Employees
- CYBR N/A
- PCVX N/A
- Industry
- CYBR Computer Software: Prepackaged Software
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- CYBR Technology
- PCVX Health Care
- Exchange
- CYBR Nasdaq
- PCVX Nasdaq
- Market Cap
- CYBR 12.4B
- PCVX 13.2B
- IPO Year
- CYBR 2014
- PCVX 2020
- Fundamental
- Price
- CYBR $305.27
- PCVX $86.51
- Analyst Decision
- CYBR Strong Buy
- PCVX Strong Buy
- Analyst Count
- CYBR 29
- PCVX 7
- Target Price
- CYBR $327.10
- PCVX $147.50
- AVG Volume (30 Days)
- CYBR 558.4K
- PCVX 1.4M
- Earning Date
- CYBR 11-13-2024
- PCVX 11-05-2024
- Dividend Yield
- CYBR N/A
- PCVX N/A
- EPS Growth
- CYBR N/A
- PCVX N/A
- EPS
- CYBR 0.27
- PCVX N/A
- Revenue
- CYBR $909,462,000.00
- PCVX N/A
- Revenue This Year
- CYBR $27.72
- PCVX N/A
- Revenue Next Year
- CYBR $23.19
- PCVX N/A
- P/E Ratio
- CYBR $1,050.02
- PCVX N/A
- Revenue Growth
- CYBR 30.31
- PCVX N/A
- 52 Week Low
- CYBR $185.04
- PCVX $48.24
- 52 Week High
- CYBR $318.16
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- CYBR 62.39
- PCVX 23.31
- Support Level
- CYBR $288.00
- PCVX $101.87
- Resistance Level
- CYBR $318.16
- PCVX $107.31
- Average True Range (ATR)
- CYBR 10.62
- PCVX 5.82
- MACD
- CYBR 1.56
- PCVX -2.04
- Stochastic Oscillator
- CYBR 72.27
- PCVX 3.58
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader within that subsegment, with more than half of the Fortune 500 CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While historically, CyberArk has sold its security solutions primarily via on-premises licenses, over the past few years, it has transitioned to a subscription, recurring revenue model.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.